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ABSTRACT 
Methotrexate (MTX) is a widely used anti-cancer and anti-rheumatic drug that has been 
postulated to protect against metabolic risk factors associated with type 2 diabetes mellitus, 
although the mechanism remains unknown. MTX inhibits 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase / inosine monophosphate cyclohydrolase (ATIC) and 
thereby slows down the metabolism of ZMP and its precursor AICAR, which is a 
pharmacological AMPK activator. We explored whether MTX promotes AMPK activation in 
cultured myotubes and isolated skeletal muscle. We found MTX markedly reduced the 
threshold for AICAR-induced AMPK activation, and potentiated glucose uptake and lipid 
oxidation. Gene silencing of the MTX target ATIC activated AMPK and stimulated lipid 
oxidation in cultured myotubes. Furthermore, MTX activated AMPK in wild-type HEK-293 
cells. These effects were abolished in skeletal muscle lacking the muscle-specific, ZMP-
sensitive AMPK-γ3 subunit and in HEK-293 cells expressing a ZMP-insensitive mutant 
AMPK-γ2 subunit. Collectively, our findings underscore a role for AMPK as a direct 
molecular link between MTX and energy metabolism in skeletal muscle. Co-therapy with 
AICAR and MTX could represent a novel strategy to treat metabolic disorders and overcome 
current limitations of AICAR mono-therapy. 
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INTRODUCTION 
Chronic therapy with methotrexate (MTX), a broadly used anti-cancer and anti-rheumatic 
drug, may protect rheumatic patients against metabolic risk factors associated with 
cardiovascular disease, obesity (1) and type 2 diabetes (2). This notion is supported by recent 
observations that MTX alleviates hyperglycemia and insulin resistance in diabetic (db/db) 
mice (3) and obese mice fed a high-fat diet (4). MTX is a folate antagonist and inhibits DNA 
replication (5), which explains its anti-cancer action, but the not improvements in glucose 
homeostasis in type 2 diabetes or obesity. Suppression of chronic inflammation, thought to 
arise from MTX-stimulated adenosine release (6), may improve glucose homeostasis 
indirectly (7). Since anti-rheumatic drugs are not invariably associated with metabolic 
protection (1, 8), other mechanisms are likely. While MTX-induced adenosine release may 
have direct metabolic effects (4), its exact role is ambiguous, since both adenosine receptor 
activation (9) and blockage (10) improves insulin sensitivity. Clearly the molecular 
underpinnings of MTX action in relation to metabolic disease remain undefined. 
MTX has several pharmacological targets, including 5-aminoimidazole-4-
carboxamide ribonucleotide formyltransferase / inosine monophosphate cyclohydrolase 
(ATIC) (11). ATIC is essential for the conversion of 5-aminoimidazole-4-carboxamide-1-β-
D-ribofuranosyl-5’-monophosphate (ZMP) to inosine monophosphate in the final two steps of 
the de novo purine synthesis pathway. Thus, congenital ATIC deficiency or MTX therapy 
elevates intracellular ZMP content and excretion of its metabolites (6, 12, 13). The purine 
precursor ZMP is also an AMP-mimetic and activates the AMP-activated protein kinase 
(AMPK) (14). AMPK is a heterotrimeric serine-threonine kinase, composed of the catalytic α 
and non-catalytic β and γ subunits (15). ZMP binds to the AMP-binding sites on the γ 
subunits (16), and this is required for its ability to activate AMPK (17). AMPK plays a role in 
maintaining energy homeostasis and is currently a target for the treatment of type 2 diabetes 
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(18-20). Thus, MTX might mitigate metabolic impairments by promoting ZMP-stimulated 
AMPK activation in key organs controlling glucose homeostasis. 
AMPK activation increases glucose uptake, fatty acid oxidation and mitochondrial 
biogenesis, which helps to ameliorate different aspects of metabolic dysregulation, including 
hyperglycemia and insulin resistance (19). MTX could promote ZMP accumulation and 
AMPK activation by suppressing ATIC, which is expressed and active in skeletal muscle (21, 
22). ZMP is also the active metabolite of the pharmacological AMPK activator 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) (14). AICAR therapy 
promotes favorable metabolic reprogramming in skeletal muscle of sedentary (23) and 
diabetic (ob/ob) mice (24). However, a relatively high threshold for AMPK activation (25), in 
conjunction with poor bioavailability (26), limits the usefulness of AICAR in the treatment of 
type 2 diabetes (27). MTX may enhance AICAR-stimulated AMPK activation in skeletal 
muscle by suppressing ATIC-mediated ZMP clearance and overcome this problem. 
Here, we show that MTX markedly reduces the threshold for AICAR-stimulated 
AMPK activation and potentiates glucose uptake and lipid oxidation in skeletal muscle. Thus, 
co-therapy with AICAR and MTX could represent a novel strategy to treat metabolic 
disorders and overcome current limitations of AICAR mono-therapy.  
  
METHODS 
Antibodies and reagents 
Antibodies against phospho-AMPKα (Thr172) and phospho-ACC (Ser79) were from Cell 
Signaling Technology (Beverly, MA), the antibody against ATIC was from Sigma-Aldrich 
(Stockholm, Sweden), the GLUT4 antibody was from Millipore (Temecula, CA), and the 
antibody against GAPDH was from Santa Cruz Biotechnology (Santa Cruz, CA). ECL 
reagent and the protein molecular weight marker were from GE Healthcare (Uppsala, 
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Sweden). BCA Protein Assay kit was from Pierce (Rockford, IL), and PVDF Immobilon-P 
membrane from Millipore (Bedford, MA). Cell culture materials were from Costar (Täby, 
Sweden). [9-10(n)-3H]-palmitic acid and [1,2-3H]-2-deoxy-D-glucose were from Perkin-
Elmer. All other reagents, unless otherwise specified, were of analytical grade and obtained 
from Sigma-Aldrich (Stockholm, Sweden). 
L6 cells and siRNA transfection  
L6 muscle cells were grown in αMEM supplemented with 10% fetal bovine serum (FBS), 1% 
PeSt (100 U/ml penicillin and 100 µg/ml streptomycin), and 1% Fungizone at 37°C in 
humidified air/5% CO2. They were differentiated into myotubes in αMEM (2% FBS, 1% PeSt 
and 1% Fungizone). L6 cells were transfected with a pool of siRNAs (100 nM) against ATIC 
mRNA or scrambled siRNA (Dharmacon; Chicago, IL) using CellPhect Transfection Kit on 
days 2 and 4 of differentiation. Experiments were performed 48–72 hours after the last 
transfection. 
Primary human skeletal muscle cells 
Primary human skeletal muscle myoblasts were from Lonza Group Ltd (Basel, Switzerland) 
and maintained in DMEM/F12 supplemented with 20% FBS, 1% PeSt and 1% Fungizone at 
37°C in humidified air/7% CO2. Myoblasts were differentiated into myotubes for 5 days in 
DMEM (2% FBS, 1% PeSt and 1% Fungizone). Serum-starved myotubes were incubated for 
4 hours and subsequently with or without 5 µM MTX and/or 0.2 mM AICAR for 5 hours. 
Metabolic assays in L6 myotubes  
L6 myotubes were incubated in αMEM (w/o nucleosides) with or without 5 µM MTX for 16 
hours prior to the experiment. For fatty acid oxidation, myotubes were serum-starved for 4 
hours and then incubated with or without MTX (5 µM) and/or AICAR (0.2 or 2 mM) for 5 
hours in αMEM, supplemented with 0.2% BSA, 20 µM cold palmitate and 0.5 µCi/ml [3H]-
palmitic acid. Palmitate oxidation was determined by measuring the amount of 3H2O in cell 
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culture media. Non-metabolized palmitate was adsorbed to charcoal and removed by 
centrifugation (16,000 rpm, 15 minutes). For glucose uptake, L6 myotubes were incubated 
with or without MTX (5 µM) and/or AICAR (0.2 mM or 2 mM) in serum-free αMEM (w/o 
nucleosides) for 5 hours. Myotubes were then washed with HBS (140 mM NaCl, 20 mM 
Hepes, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2, pH 7.4) and subsequently incubated in 
HBS supplemented with 10 µM 2-deoxy-D-glucose and 0.75-1 µCi/ml [1,2-3H]-2-deoxy-D-
glucose for 10 minutes. Nonspecific glucose transport was assessed in the presence of 10 µM 
cytochalasin B. Myotubes were then washed with ice-cold stop solution (25 mM glucose, 
0.9% (w/v) NaCl) and lysed in 0.03% (w/v) SDS. Radioactivity was measured in cell lysates 
by liquid scintillation counting.  
Experimental animals 
This study was approved by the Regional Animal Ethical Committee (Stockholm, Sweden). 
AMPK-γ3 knock-out (AMPK-γ3-/-) mice were bred onto a C57BL/6 genetic background and 
have been thoroughly characterized (28). Prior to all experiments, AMPK-γ3-/- and wild-type 
mice were fasted for 4 hours before being anesthetized with Avertin (0.02 ml/g i.p.). 
Metabolic assays in isolated skeletal muscle 
Extensor digitorum longus (EDL) and soleus muscle from wild-type or AMPK-γ3-/- mice were 
preincubated at 30°C in oxygenated (95% O2/5% CO2) Krebs-Henseleit bicarbonate buffer 
(KHB) supplemented with 5 mM glucose, 15 mM mannitol, 5 mM HEPES and 0.1% (w/v) 
BSA with or without 10 µM MTX for 2 hours. Thereafter, muscles were incubated for 2-hour 
with or without 10 µM MTX and/or AICAR (0.2 mM or 2 mM). Glucose transport was 
assessed by measuring the uptake of [1,2-3H]-2-deoxy-D-glucose as described (28). Muscles 
were incubated in KHB supplemented with 1 mM 2-deoxy-D-glucose, 19 mM of mannitol,  
2.5 µCi/ml of [1,2-3H]-2-deoxy-D-glucose and 0.7 µCi/ml of [14C] mannitol for 20 minutes. 
For fatty acid oxidation, KHB was supplemented with [H3]-palmitic acid (0.4 µCi/ml) and 0.3 
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mM cold palmitate and oxidation was determined by analyzing the [3H]-labeled water content 
using liquid scintillation counting as described above. 
Lysate preparation and immunoblot analysis  
Myotubes were washed with ice-cold PBS and lysed in homogenization buffer (1% Protease 
Inhibitor Cocktail, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5 mM Na4P2O7, 0.5 mM 
Na3VO4, 1% Triton X-100, 10% glycerol, 20 mM Tris, 10 mM NaF, 1 mM EDTA and 0.2 
mM phenylmethylsulfonyl fluoride, pH 7.8). Lysates were subjected to centrifugation for 15 
minutes at 12,000 x g (4°C). Muscle was homogenized in ice-cold buffer, followed by end-
over-end rotation for 60 minutes (4°C) and centrifugation at 12,000 x g for 10 minutes (4°C). 
Supernatants of cell or muscle lysates were collected and protein content was measured (BCA 
Protein Assay). Proteins dissolved in Laemmli buffer (25µg per well) were resolved on 4-12% 
Bis-Tris gel (Bio-Rad, Richmond, CA), transferred to PVDF membrane and blocked with 
7.5% non-fat milk  and probed overnight  (4oC) with primary antibodies. All primary 
antibodies were diluted 1:1,000 in primary antibody buffer (Tris-buffered saline (TBS), 0.5% 
BSA, 0.5% NaN3, pH 7.6). Following the overnight incubation, membranes were washed with 
washing buffer (TBS, 0.02% Tween-20) and incubated with appropriate horseradish 
peroxidase-conjugated secondary antibodies (Bio-Rad) for 1 hour at room temperature. The 
secondary antibodies were diluted 1:25,000 in TBS supplemented with 5% non-fat milk. 
Immunoreactive proteins were visualized by enhanced chemiluminiscence and quantified by 
the Quantity One 1-D Analysis Software (Bio-Rad). Data were normalized to GAPDH. 
Plasmids and generation of stable wild-type and R531G AMPK-γ2 HEK-293 cell lines 
Full-length human γ2 was amplified with primers designed to encode a 5’-BamHI site and a 
C-terminal FLAG tag followed by an XhoI site. The resulting PCR product was cloned into 
the pcDNA5/FRT/TO plasmid (Invitrogen) to create pcDNA5/FRT/TO/g2. Mutagenesis of 
the construct was performed using the QuikChange Site-Directed Mutagenesis system 
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(Stratagene). The plasmid (POG44) expressing Flp recombinase was from Invitrogen. T-Rex 
HEK-293 cells containing a single FRT site (Invitrogen) were transfected with Fugene6 
(Promega) using the plasmids POG44 and pcDNA5/FRT/TO/g2 at a ratio of 9:1. Fresh 
medium was added to the cells 24 hours after transfection, and media containing 200 µg/ml 
hygromycin B and 15 µg/ml blasticidin was added 48 hours after transfection. The medium 
was replaced every 3 days until foci could be identified, and individual foci were then 
selected and expanded. The expression of FLAG-tagged g2 was induced by adding 1 µg/ml 
tetracycline for 40 hours, and expression detected using immunofluorescence microscopy and 
Western blot using anti-FLAG antibodies. 
Culture of wild-type and R531G AMPK-γ2 HEK-293 cells and cell treatments 
HEK-293 cells expressing wild-type or R531G AMPK-γ2 were generated as described (17). 
T-Rex-Flp-In HEK-293 cells (Invitrogen) containing a single FRT site were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/L glucose, 10% (v/v) FBS, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 15 µg/ml blasticidin and 100 µg/ml zeocin. 
After transfection, T-Rex-Flp-In HEK-293 cells stably expressing either WT or R531G 
AMPK-γ2 were cultured as above except that zeocin was replaced by 200 µg/ml hygromycin 
B. Forty hours after the induction of protein, 3 µM MTX/DMSO was added to cells for 16 
hours, followed by 1 hour of AICAR in different concentrations. 
AMPK activity assays  
Wild-type HEK-293 cells or RG cells were assayed for AMPK activity as described (17). 
Activity of the purified rat liver AMPK, which is approximately an equal mixture of the 
α1β1γ1 and α2β1γ1 heterotrimer (29), was measured in the presence or absence of AMP or 
PP2C as described (30). 
Statistics 
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Results are presented as means±SEM or means±SD. Comparisons between multiple groups 
were performed using ANOVA, followed by Bonferroni’s or Dunnett’s post hoc test.  
Student’s t-test was used when two groups were compared. Statistical significance was 
established at P<0.05.   
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RESULTS 
MTX promotes AMPK activation in cultured myotubes 
To determine whether MTX modulates AMPK activation, L6 myotubes and primary 
human myotubes were exposed to 5 µM MTX and sub-threshold (0.2 mM) and/or maximally 
effective (2 mM) concentrations of AICAR (14, 25). AMPK activation was determined by 
measuring AMPK Thr172 and acetyl-CoA carboxylase Ser79 (ACC) phosphorylation. 
Exposure of cultured myotubes to 0.2 mM AICAR alone did not elevate AMPK or ACC 
phosphorylation (Fig. 1A-D), demonstrating that 0.2 mM AICAR is below the threshold for 
AMPK activation. Conversely, co-incubation with MTX and 0.2 mM AICAR robustly 
increased phosphorylation of AMPK (Fig. 1A, B) and ACC (Fig. 1C, D), demonstrating 
MTX markedly reduces the threshold for AMPK activation.   
MTX promotes metabolic effects in skeletal muscle via AMPK activation  
To investigate whether the augmented AICAR-stimulated ACC phosphorylation in 
MTX-treated myotubes translates into increased lipid utilization, palmitate oxidation was 
measured in L6 myotubes incubated with 5 µM MTX and/or AICAR (0.2 or 2 mM). While 
0.2 mM AICAR alone failed to increase palmitate oxidation, treatment with 0.2 mM AICAR 
and MTX together stimulated palmitate oxidation in L6 myotubes (Fig. 2A).  
 We next examined whether AICAR-stimulated glucose uptake is augmented in L6 
myotubes after exposure to 5 µM MTX (Fig. 2B). Although exposure of L6 myotubes to 0.2 
mM AICAR alone failed to stimulate glucose uptake, a combined treatment with 0.2 mM 
AICAR and MTX markedly elevated glucose uptake. MTX enhanced glucose uptake in 
myotubes treated with saturating concentration of AICAR (2 mM), indicating AICAR 
responsiveness was improved. Glucose transport was also determined in EDL and soleus 
muscle treated with 2 mM AICAR and/or 10 µM MTX (Fig. 2C). MTX robustly augmented 
AICAR-stimulated glucose uptake in EDL muscle, underscoring the effect of MTX to 
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potentiate AICAR responsiveness. Although soleus muscle was less responsive to AICAR, 
glucose uptake was elevated upon MTX and AICAR exposure. MTX treatment did not affect 
GLUT4 protein abundance or GLUT4 mRNA expression (data not shown). 
MTX promotes AMPK activation through indirect mechanisms 
To confirm that MTX treatment inhibited ATIC, ZMP content was measured in L6 
cells exposed to 0.2 mM AICAR and/or 5 µM MTX. AICAR alone did not elevate ZMP 
content, indicative of the high ZMP turnover (Fig.3A). However, a combined treatment with 
MTX and 0.2 mM AICAR robustly increased the ZMP:ATP ratio. MTX exposure suppresses 
de novo purine synthesis (31) and may provoke ATP depletion in some situations (32, 33). 
ATP depletion decreases adenylate energy charge (Table 1), which stimulates AMPK 
activation directly (34). Given that the AMP concentration in cultured myotubes was too low 
for reliable quantitative estimation of energy charge, we determined the ADP:ATP ratio as a 
marker of cellular energy status (17). MTX exposure, in the absence or presence of AICAR, 
increased the ADP:ATP ratio 24-28% (Fig. 3B), indicating a modest degree of energy stress. 
The observed increases in the ZMP content and the ADP:ATP ratio provide evidence that 
MTX promotes AMPK activation in cultured myotubes primarily by decreasing ZMP 
clearance, although ATP depletion may play a secondary role. 
To establish a causal link between MTX-induced alterations in cellular nucleotide 
content and AMPK activation, wild-type HEK-293 and mutant HEK-293 (RG) cell lines 
were exposed to MTX (3 µM) and different concentrations of AICAR (Fig. 3C-F). RG cells 
harbor a single substitution (R531G) within the AMPK-γ2 subunit, which renders AMPK 
insensitive to stimulation by AMP and ZMP (17). Both ZMP content and the ADP:ATP ratio 
were increased in wild-type cells treated with MTX and AICAR (Fig. 3C, D). The elevated 
ZMP content during MTX and AICAR treatment was paralleled by an increase in AMPK 
activity (Fig. 3E). Notably, MTX alone was sufficient to activate AMPK in wild-type cells. 
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However, the increase in AMPK activity was almost entirely abrogated in RG cells during 
co-incubation with MTX and AICAR (Fig. 3F), and MTX alone did not stimulate AMPK 
activation in RG cells. Since AMPK complexes in RG cells remain responsive to direct 
AMPK activators other than AMP and ZMP such as A-769662 (17), this suggests that MTX 
is not a direct AMPK activator.  
MTX is not a direct AMPK activator 
To evaluate whether MTX activates AMPK allosterically, the activity of AMPK, 
purified from rat liver, was measured during incubation with AMP and/or increasing 
concentrations of MTX (Fig. 4A). AMPK activity was increased in the presence of 200 µM 
AMP, but MTX alone or in combination with AMP did not alter AMPK activity. We also 
determined whether MTX protects AMPK from dephosphorylation by protein phosphatase 
2C (PP2C), which dephosphorylates and thereby inactivates AMPK (35). Purified AMPK 
was incubated with PP2C and either 200 µM AMP or different concentrations of MTX (Fig. 
4B). AMP almost completely prevented the inactivation of AMPK by PP2C, but MTX did 
not, showing that MTX does not inhibit PP2C-mediated dephosphorylation of AMPK. 
MTX is dependent on AMPK to promote lipid oxidation 
Our results have established that MTX enhances AICAR action in skeletal muscle. To 
determine whether MTX depends on AMPK to promote metabolic alterations in skeletal 
muscle, we studied EDL and soleus muscles from wild-type and AMPK-γ3-/- knock-out mice. 
Isolated EDL and soleus muscles were incubated in the absence or presence of 10 µM MTX 
and/or a sub-threshold concentration of AICAR (0.2 mM). Treatment with 0.2 mM AICAR 
and MTX was sufficient to markedly stimulate AMPK activation and palmitate oxidation in 
wild-type EDL and soleus muscles (Fig. 5). However, co-incubation with MTX and 0.2 mM 
AICAR did not stimulate phosphorylation of AMPK (Fig. 5A) and ACC (Fig. 5C) in AMPK-
γ3-/- EDL muscle. MTX also failed to enhance AICAR-stimulated palmitate oxidation in 
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AMPK-γ3-/- EDL muscle (Fig. 5E), supporting the notion that MTX promotes these 
metabolic alterations through AMPK. Due to low expression of AMPK-γ3 in wild-type 
soleus muscle (36), the response to a combined treatment with MTX and 0.2 mM AICAR 
was similar between soleus muscles from wild-type and AMPK-γ3-/- mice (Fig. 5B, D, F). 
To establish whether MTX promotes AMPK activation by decreasing ZMP clearance, 
nucleotide content was measured. ZMP content was markedly elevated upon addition of 
AICAR in wild-type EDL and soleus muscle (Table 1). Although MTX markedly augmented 
AICAR-stimulated AMPK activation and palmitate utilization, it did not enhance ZMP 
accumulation in EDL and soleus muscle. Adenylate energy charge also remained unaltered 
upon MTX treatment (Table 1). These results suggest that diminished ZMP clearance and/or 
energy depletion are not the exclusive mechanisms underlying an MTX-induced reduction in 
the threshold for AICAR-stimulated AMPK activation in skeletal muscle.   
Suppression of ATIC directly promotes AMPK activation and increases lipid oxidation  
L6 myotubes were utilized to validate ATIC as an MTX target (Fig. 6A). Expression 
of ATIC was suppressed in L6 myotubes using siRNA (Fig. 6B). Exposure of myotubes 
transfected with scrambled siRNA to 0.2 mM AICAR did not increase ZMP content (Fig. 
6C). Conversely, stimulation with 0.2 mM AICAR robustly elevated ZMP content in ATIC-
depleted myotubes (Fig. 6C), indicating diminished ZMP clearance. The ADP:ATP ratio was 
also elevated 12-15% in ATIC-depleted cells (Fig. 6D), possibly reflecting purine depletion 
due to decreased de novo synthesis. The increased ZMP content in ATIC-depleted myotubes 
treated with AICAR increased AMPK and ACC phosphorylation and palmitate oxidation 
(Fig. 6E-G), consistent with the hypothesis that decreased ZMP clearance promotes AMPK 
activation. Notably, ATIC depletion alone increased AMPK phosphorylation and palmitate 
oxidation (Fig. 6E, G), underscoring the link between ATIC suppression and AMPK 
activation in skeletal muscle. 
14 
 
Gene silencing suppressed ATIC expression 70% (Fig. 6B). To test whether 
inhibition of residual ATIC activity provides an additional stimulus for AMPK activation, L6 
myotubes were transfected with siRNA and subsequently exposed to MTX and incubated in 
the presence of 0.2 mM AICAR. In ATIC-depleted myotubes, MTX robustly stimulated 
AMPK and ACC phosphorylation, as well as palmitate oxidation (Fig. 6H-J). ATIC 
depletion in conjunction with MTX exposure achieved maximal AMPK activation, since 
incubation with 0.2 mM AICAR failed to exert an additional effect. However, a combined 
treatment with 0.2 mM AICAR and MTX triggered a similar response in control myotubes 
transfected with scrambled siRNA.  
 
DISCUSSION 
Epidemiological (1, 2) and experimental (3, 4) evidence suggest that MTX may 
protect against type 2 diabetes, but the underlying mechanisms have been unclear. We 
provide evidence that MTX potentiates AICAR-stimulated AMPK activation and glucose 
uptake and lipid oxidation in skeletal muscle. We also demonstrate that suppression of ATIC, 
a well-characterized MTX target (11), directly promotes AMPK activation in cultured 
myotubes. Finally, MTX alone is sufficient to stimulate AMPK activation in HEK-293 cells. 
These results highlight a role for AMPK as link between MTX and skeletal muscle energy 
metabolism. 
Pharmacological activation of AMPK in skeletal muscle represents a promising 
strategy to bypass insulin-resistant pathways, in order to stimulate glucose uptake and 
improve insulin sensitivity in type 2 diabetes (19). However, the search for peripheral AMPK 
activators has been challenging. AMPK activators, such as A-769662, target AMPK-β1 
complexes that are poorly expressed in skeletal muscle (37, 38), whereas AICAR has clinical 
limitations due to its poor bioavailability (18, 26). Even with intravenous infusion, the plasma 
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concentration of AICAR (0.16-0.18 mM) remains below the threshold for AMPK activation 
in skeletal muscle (27, 39). Here we report co-incubation with 0.2 mM AICAR and MTX 
activates AMPK and stimulates glucose uptake and lipid oxidation in skeletal muscle. These 
results are consistent with effects of MTX on AICAR in cancer cells (32). Thus, combined 
therapy with MTX and AICAR might provide a novel pharmacological strategy to overcome 
current limitations of AICAR mono-therapy. 
AMPK-γ3 is the muscle-specific isoform of the AMP- and ZMP-sensitive AMPK-γ 
subunit, which exists in three isoforms (γ1-γ3) (40), and a major isoform involved in exercise-
induced AMPK activation (41). Although AMPK-γ3 is expressed primarily in glycolytic 
muscles (28, 36), a complete failure of MTX to enhance AICAR action in AMPK-γ3-/- EDL 
muscle was unexpected since AMPK-γ1 and -γ2 isoforms are also expressed (36). 
Furthermore, MTX enhanced AICAR-stimulated AMPK phosphorylation in wild-type and 
AMPK-γ3-/- soleus muscle, despite low endogenous expression in wild-type soleus muscle 
(28, 36). Thus, in glycolytic skeletal muscle, MTX preferentially promotes activation of 
AMPK-γ3-containing complexes. The γ3 subunit offers an entry point to tissue-specific 
regulation of AMPK function, and a possible therapeutic target for treatment of insulin 
resistance in type 2 diabetes (28). Activating mutations in the γ3 isoform are associated with 
skeletal muscle remodeling analogous to exercise training, including augmented 
mitochondrial biogenesis, and fat oxidation, as well as protection against insulin resistance 
(28, 42). Co-therapy with MTX and AICAR may therefore promote a plethora of beneficial 
metabolic alterations, including mimicking the effects of exercise training (23).  
MTX promotes AMPK activation in cultured myotubes and WT cells primarily via 
inhibition of ATIC, while ATP depletion may also have a secondary role. However, MTX did 
not inhibit ATIC or evoke energy depletion in murine EDL and soleus muscles, although 
AICAR action was markedly enhanced. This failure to suppress ATIC activity may be 
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explained by the fact that MTX is an efficient ATIC inhibitor only after MTX polyglutamates 
are formed by the action of folylpolyglutamate synthetase, which is a slow process (11). Thus, 
the exposure time during the isolated skeletal muscle incubation may have been insufficient 
for MTX to depress ATIC activity. While our data do not exclude a role for ATIC inhibition 
during chronic MTX therapy, they nevertheless suggest that MTX promotes AMPK activation 
through additional, ATIC-independent mechanisms. This ATIC-independent pathway appears 
to be operate independent of any activation of up-stream kinases like LKB1, which 
phosphorylate AMPK at Thr172 (15). Indeed, MTX alone failed to activate AMPK in RG 
cells, although they are normally responsive to AMPK activators other than ZMP and AMP 
(17). However, MTX decreases the concentration of S-adenosylmethionine (43), a biological 
methyl group donor that promotes AMPK inactivation (44), which may provide one possible 
ATIC-independent pathway. 
MTX has several targets aside from ATIC (11), which may also modulate AMPK 
activation. In particular, the activity of glycinamide ribonucleotide transformylase (GART), 
an enzyme upstream of ATIC in the de novo pathway of purine synthesis (Fig. 7), may 
critically determine the level of endogenous ZMP. Concurrent inhibition of ATIC and GART 
by MTX suppresses the entire de novo synthesis pathway and decreases endogenous ZMP 
formation (31). This provides a possible explanation why MTX alone did not increase the 
content of endogenous ZMP in cultured myotubes, although the clearance of ZMP derived 
from AICAR was decreased. Similarly, MTX increases ZMP content and enhances AMPK 
activation in AICAR-treated cancer cells, but not when used alone (32). Conversely, ATIC 
depletion elevated basal AMPK phosphorylation and palmitate oxidation in cultured 
myotubes, suggesting selective inhibition of ATIC in skeletal muscle may introduce a 
metabolic block leading to ZMP accumulation and AMPK activation.  
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MTX has a greater propensity to inhibit ATIC than GART (11, 31). Patients receiving 
low-dose MTX exhibit increased urinary excretion of 5-aminoimidazole-4-carboxamide (13), 
a ZMP degradation product, which is indicative of ZMP accumulation due to ATIC 
inhibition. Conversely, high-dose MTX fails to increase urinary excretion of endogenous 
AICAR (45). Scaling down MTX dosage may create a therapeutic window for more selective 
ATIC inhibition with subsequent ZMP accumulation and AMPK activation in skeletal muscle 
and other metabolic tissues. Consistent with this hypothesis, low-dose MTX therapy increased 
intracellular ZMP content in mice (6). Furthermore, low-dose MTX mono-therapy increases 
skeletal muscle GLUT4 abundance in diabetic (db/db) mice (3) and suppresses adipose tissue 
lipolysis in obese mice (4), consistent with AMPK activation in skeletal muscle (24, 46) and 
adipose tissue (14), respectively. Finally, we report MTX alone is sufficient to induce AMPK 
activation in HEK-293 cells, thus providing proof of concept that MTX acts as AMPK 
activator, rather than just as an enhancer of effects of AICAR.  
We show that MTX enhances AICAR-stimulated AMPK activation in skeletal muscle 
as well as in cells of kidney origin (HEK-293 cells). Taken together with studies in different 
types of cancer cells (31, 32), these data suggest that MTX potentiates effects of AICAR not 
only in skeletal muscle, but also in other organs. For instance, ATIC is expressed and active 
in heart (21, 47), indicating MTX could enhance AICAR action in cardiomyocytes. Also, 
liver expresses ATIC (47) and MTX-treated hepatic carcinoma cells release adenosine (48), 
which results from MTX-induced ATIC inhibition (6). Consistent with the involvement of 
ATIC, we determined that MTX enhances ZMP accumulation and AMPK activation in 
AICAR-treated H4IIE cells of liver origin (data not shown). Aside from ATIC expression, 
differences in MTX uptake might also determine tissue responsiveness to co-therapy with 
AICAR and MTX. Indeed, cells lacking MTX transporters are resistant to MTX despite ATIC 
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expression (32, 49). Collectively, these studies indicate that MTX is likely to enhance AICAR 
action in all tissues that express ATIC and MTX uptake transporters. 
In conclusion, MTX markedly reduces the threshold for AICAR-induced AMPK 
activation and increases glucose uptake and lipid oxidation in skeletal muscle. The underlying 
mechanisms include reduced ZMP clearance due to ATIC inhibition and ATP depletion, as 
well as ATIC-independent effects. Collectively, our results highlight a role for AMPK as a 
direct link between MTX and energy metabolism. Co-therapy with AICAR and MTX or 
another MTX-based agent represents a novel strategy to treat metabolic disorders and 
overcome current limitations of AICAR mono-therapy. 
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FIGURE LEGENDS 
Figure 1. MTX promotes AMPK activation in cultured myotubes. (A, B) Phosphorylation of 
AMPK (at Thr172) and its target (C, D) ACC (at Ser79) were determined in L6 myotubes and in 
primary human myotubes (HSMC) upon exposure to 5 µM MTX and/or 0.2 mM or 2 mM AICAR (5 
hr). Myotubes were preincubated with 5 µM MTX or vehicle for 16 hr prior to the experiment. 
Results are means ± SEM (n=6). #P<0.05 vs. Basal, *P<0.05 vs. AICAR (0.2 mM). 
Figure 2. MTX promotes metabolic effects in skeletal muscle via AMPK activation. (A) Palmitate 
oxidation (n=7-8, except Basal and MTX, where n=15) and (B) glucose uptake (n=24) in L6 myotubes 
upon exposure to 5 µM MTX and/or 0.2 mM or 2 mM AICAR (5 hr). L6 myotubes were preincubated 
with 5 µM MTX or vehicle for 16 hr prior to the palmitate oxidation or glucose uptake assay. (C) 
Glucose uptake in isolated EDL (black bars) and soleus (white bars) muscle after exposure to 10 µM 
MTX, 120 nM insulin and/or 2 mM AICAR (n=6-8). EDL and soleus muscle were preincubated with 
10 µM MTX or vehicle for 2 hr prior to the glucose uptake assay. Results are means ± SEM. #P<0.05 
vs. Basal, *P<0.05 vs. AICAR (0.2 mM) or as indicated. 
Figure 3. MTX promotes AMPK activation through indirect mechanisms. (A) ZMP content and 
(B) the ADP:ATP ratio in L6 myotubes exposed to 5 µM MTX and/or 0.2 mM AICAR (5 hr). L6 
myotubes were preincubated with 5 µM MTX or vehicle for 16 hr prior to the experiment. Results are 
means ± SEM (n=3-5). (C) ZMP content and (D) the ADP:ATP ratio in WT cells exposed to 3 µM 
MTX and/or different concentrations of AICAR. Means ± SD (n=2). Activity of AMPK in (E) WT 
cells and (F) RG cells exposed to 3 µM MTX and/or different concentrations of AICAR (1 hr). WT 
and RG cells were preincubated with 3 µM MTX (black circles) or vehicle (white circles) for 16 hr 
prior to the AMPK activity assay. Results are means ± SEM (n=2-4). AMPK activity is expressed as 
percentage of the activity in controls without added treatments. Results are means ± SEM (n=11-12). 
*P<0.05 vs. without MTX or as indicated. 
Figure 4. MTX is not a direct AMPK activator. (A) Activity of purified rat liver AMPK was 
measured following incubation with increasing concentrations of MTX in the absence (white bars) or 
presence (black bars) of 200 µM AMP. (B) Activity of purified rat liver AMPK before (white bars) 
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and after 10-minute incubation with PP2C (black bars) in the presence or absence of MTX (1-30 µM) 
or 200 µM AMP. AMPK activities are expressed as percentages of activity in the controls without 
added treatments. Results are means ± SD (n=2). 
Figure 5. MTX is dependent on AMPK to promote lipid oxidation in isolated skeletal muscle. (A, 
B) Phosphorylation of AMPK and (C, D) its target ACC and (E, F) palmitate oxidation were measured 
in wild-type (black bars) or AMPK-γ3-/- (white bars) EDL and soleus muscle after exposure to 10 µM 
MTX and/or 0.2 mM AICAR (2 hr). EDL and soleus muscle were preincubated with 10 µM MTX or 
vehicle for 2 hr prior to the experiment. Results are means ± SEM (n=12). *P<0.05 vs. AICAR 
Figure 6. Suppression of ATIC promotes AMPK activation and increases lipid oxidation in L6 
myotubes by a direct mechanism. (A) ATIC expression was determined by immunoblot in L6 
myotubes, differentiated primary human skeletal muscle cells (HSMC), HEK-293 cells and in murine 
EDL and soleus muscle. (B) ATIC protein expression in L6 myotubes after transfection with 
scrambled siRNA (Scr) or siRNA against ATIC (siATIC). (C) ZMP content, (D) the ADP:ATP ratio, 
(E) AMPK phosphorylation, (F) ACC phosphorylation and (G) palmitate oxidation measured in 
control or ATIC-depleted L6 myotubes upon exposure to 0.2 mM AICAR (5 hr). Results for 
nucleotide measurements are means for Basal (n=2) and means ± SEM (n=4) for AICAR. For all 
others results are means ± SEM (n=8). #P<0.05 vs. Basal (Scr), *P<0.05 vs. AICAR (Scr). (H-J) 
ATIC-depleted or control L6 myotubes were preincubated with 5 µM MTX for 16 hr. (H) AMPK 
phosphorylation, (I) ACC phosphorylation and (J) palmitate oxidation were determined upon exposure 
to 0.2 mM AICAR (5 hr). Results are means ± SEM (n=6). *P<0.05 vs. MTX (Scr). 
Figure 7. MTX promotes AMPK activation in skeletal muscle through different mechanisms. 
Clearance of AICAR through the de novo purine synthesis pathway limits effectiveness of AICAR as 
an AMPK activator in skeletal muscle. Co-therapy with AICAR and MTX may overcome these 
limitations by reducing the threshold for AMPK activation in skeletal muscle. Underlying mechanisms 
include diminished ZMP clearance and energy deprivation. However, other ATIC-independent 
mechanisms are likely involved. AICA: 5-aminoimidazole-4-carboxamide, GART: glycinamide 
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ribonucleotide transformylase, IMP: inosine monophosphate, PRPP: 5-phosphoribosyl-1-
pyrophosphate. 
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Table 1 Effect of MTX on ZMP content and adenylate energy charge in AICAR-treated murine 
skeletal muscle. 
Skeletal muscle Treatment ZMP:ATP 
 
Adenylate energy 
charge 
EDL 
 
AICAR 
 
0.041 ± 0.002 
 
0.93 ± 0.005 
 
 
 
 
MTX + AICAR  
 
0.039 ± 0.002 
 
0.92 ± 0.01 
 
Soleus 
 
AICAR 
 
0.12 ± 0.013 
 
0.80 ± 0.04 
  
MTX + AICAR 
 
0.12 ± 0.016 
 
0.80 ± 0.05 
  
ZMP content, expressed as the ZMP:ATP ratio, and adenylate energy charge, calculated as ([ATP] + 
0.5[ADP]) / ([ATP] + [ADP] + [AMP]), were determined in wild-type EDL and soleus muscle after 
exposure to 0.2 mM AICAR and 10 µM MTX (2 hr). EDL and soleus muscle were preincubated with 
10 µM MTX or vehicle for 2 hr prior to the experiment. ZMP was below detection limit under basal 
conditions (data not shown). Results are means ± SEM (n=3-4). 
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